Healthcare provider profile · identity verified

Patrick Anthony Gray, MD

Geriatric Medicine · MIAMI, FL · NPI 1225075559

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	808	258
Amlodipine Besylate	Amlodipine Besylate	663	209
Losartan Potassium	Losartan Potassium	440	140
Metformin Hcl	Metformin Hcl	397	121
Rosuvastatin Calcium	Rosuvastatin Calcium	307	94
Omeprazole	Omeprazole	227	70
Nifedipine Er	Nifedipine	221	76
Hydrochlorothiazide	Hydrochlorothiazide	219	71
Gabapentin	Gabapentin	218	87
Metoprolol Succinate	Metoprolol Succinate	216	68
Eliquis	Apixaban	191	38
Pantoprazole Sodium	Pantoprazole Sodium	175	69
Tamsulosin Hcl	Tamsulosin Hcl	175	64
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	171	50
Metoprolol Tartrate	Metoprolol Tartrate	160	52
Lisinopril	Lisinopril	157	51
Levothyroxine Sodium	Levothyroxine Sodium	154	50
Furosemide	Furosemide	147	52
Hydralazine Hcl	Hydralazine Hcl	145	54
Baclofen	Baclofen	142	64
Albuterol Sulfate Hfa	Albuterol Sulfate	139	52
Clopidogrel	Clopidogrel Bisulfate	125	33
Fluticasone Propionate	Fluticasone Propionate	123	53
Diclofenac Sodium	Diclofenac Sodium	122	37
Carvedilol	Carvedilol	121	42
Montelukast Sodium	Montelukast Sodium	118	51
Simvastatin	Simvastatin	114	36
Pravastatin Sodium	Pravastatin Sodium	113	40
Glipizide	Glipizide	109	36
Ezetimibe	Ezetimibe	107	39
Glimepiride	Glimepiride	96	33
Meloxicam	Meloxicam	93	35
Trazodone Hcl	Trazodone Hcl	78	23
Glipizide Er	Glipizide	74	24
Famotidine	Famotidine	64	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	19
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	60	29
Symbicort	Budesonide/Formoterol Fumarate	60	21
Januvia	Sitagliptin Phosphate	57	18
Allopurinol	Allopurinol	55	20
Clonidine Hcl	Clonidine Hcl	55	14
Triamcinolone Acetonide	Triamcinolone Acetonide	52	14
Megestrol Acetate	Megestrol Acetate	51	22
Potassium Chloride	Potassium Chloride	48	16
Xarelto	Rivaroxaban	48	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	47	12
Sildenafil Citrate	Sildenafil Citrate	43	14
Donepezil Hcl	Donepezil Hcl	42	23
Alendronate Sodium	Alendronate Sodium	41	17
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	40	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	39	36
Finasteride	Finasteride	39	13
Rybelsus	Semaglutide	37	17
Vitamin D2	Ergocalciferol (Vitamin D2)	35	17
Escitalopram Oxalate	Escitalopram Oxalate	34	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Labetalol Hcl	Labetalol Hcl	32	11
Jardiance	Empagliflozin	30	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	30	suppressed
Benazepril Hcl	Benazepril Hcl	29	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	28	suppressed
Metformin Hcl Er	Metformin Hcl	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Synthroid	Levothyroxine Sodium	25	suppressed
Ammonium Lactate	Ammonium Lactate	24	suppressed
Atenolol	Atenolol	24	suppressed
Azithromycin	Azithromycin	24	22
Levetiracetam	Levetiracetam	24	suppressed
Torsemide	Torsemide	24	11
Alcohol Prep Pads	Alcohol Antiseptic Pads	23	suppressed
Myrbetriq	Mirabegron	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Mupirocin	Mupirocin	22	18
Amiodarone Hcl	Amiodarone Hcl	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Valsartan	Valsartan	20	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	19	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Felodipine Er	Felodipine	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	16	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	15	suppressed
Clonazepam	Clonazepam	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Linzess	Linaclotide	15	suppressed
Lumigan	Bimatoprost	15	suppressed
Methylprednisolone	Methylprednisolone	15	15
Mirtazapine	Mirtazapine	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Sertraline Hcl	Sertraline Hcl	14	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Digoxin	Digoxin	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error